SABS SAB Biotherapeutics, Inc.
Price Chart
Executive Summary
SAB Biotherapeutics (SABS) closed an underwritten public offering of 19,324,677 shares at $3.85 per share and pre-funded warrants for 2,753,246 shares at $3.8499 per warrant, raising approximately $85 million in gross proceeds. The company plans to use the funds to advance its lead candidate, SAB-142, through clinical trials for type 1 diabetes and for general corporate purposes. An additional 3,311,688-share over-allotment option remains open for 30 days.
Key Financial Metrics
Actionable Insight
Monitor for future clinical trial updates on SAB-142, especially from the ongoing Phase 2b SAFEGUARD trial in type 1 diabetes. The capital raise extends the company's runway but increases share count significantly — watch for any changes in burn rate or development timelines.
Key Facts
- SAB Biotherapeutics raised $85 million in gross proceeds through a public offering.
- Offering included 19,324,677 common shares at $3.85 and pre-funded warrants for 2,753,246 shares at $3.8499.
- Proceeds will fund clinical development of SAB-142 for type 1 diabetes, manufacturing, regulatory activities, and general corporate use.
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares.
- Jefferies, UBS, Citigroup, and Barclays acted as joint book-runners.
Financial Impact
$85 million gross proceeds, with potential for additional $12.7 million if over-allotment is exercised (3,311,688 shares × $3.85)
Risk Factors
- Significant shareholder dilution from issuance of over 22 million shares and warrants.
- Clinical-stage risk: SAB-142 may fail in trials despite funding, leading to valuation decline.
- Execution risk in advancing manufacturing and regulatory plans with new capital.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259414 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
Press Release
| $3.60 $3.36 | ▼ −6.67% | ▼ −6.37% | $3.33 (−7.50%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.62 $3.56 | ▲ +1.66% | ▲ +1.74% | $3.33 (+8.01%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $3.75 $3.85 | ▲ +2.67% | ▲ +4.82% | $3.33 (−11.20%) |
|
Mar 19, 2026
12w ago
|
8-K
| $3.78 $3.83 | ▼ −1.32% | ▼ −3.53% | $3.33 (+11.90%) |
|
Mar 18, 2026
12w ago
|
Press Release
| $3.70 $3.82 | ▼ −3.24% | ▼ −3.96% | $3.33 (+10.00%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $3.70 $3.82 | ▼ −3.24% | ▼ −3.96% | $3.33 (+10.00%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.10 $4.07 | ▼ −0.73% | ▲ +0.17% | $3.33 (−18.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access